> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Naropin Not Withdrawn Due to Safety/Efficacy
- URL: https://www.fdaweb.com/naropin-not-withdrawn-due-to-safety-efficacy/
- Published: 2023-10-18T12:00:00.000Z
- Updated: 2026-09-14T14:13:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5155591

*Federal Register* notice: FDA has determined that Fresenius Kabi USA’s Naropin (ropivacaine HCl) solution was not withdrawn due to safety or effectiveness reasons. The determination means that the agency will continue to approve ANDAs that reference the product as long as they meet relevant legal and regulatory requirements. Naropin is indicated for the production of local or regional anesthesia for surgery and for acute pain management. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-10-18/pdf/2023-22960.pdf?ref=fdaweb.com).